Agilent 2100 Bioanalyzer Microfluidics DNA/Protein Analysis Platform
Agilent
Details
-
CategoryAnalytical
-
Dimension16.0in x 6.0in x 11.0in
-
SerialDE13805453
-
Shipping TypeFedEx Ground
-
ManufacturingDoes Not Apply
-
Voltage / Hertz120V/220V / 50Hz/60Hz
Description
The Agilent 2100 Bioanalyzer, model G2939A, is a sophisticated microfluidics-based platform from Agilent designed for high-precision sample handling, separation, and data analysis. Known for integrating electrophoresis and flow cytometry, it enables accurate sizing and quantification of DNA fragments, protein applications, and gene expression sampling. The device operates easily by placing a sample on the chip and initiating a run to observe real-time data display. With a capacity for up to 12 samples, analysis run times range from 30 to 45 minutes, offering a sample volume of 1 µL and sizing range from 50 to 7000 bp. This used unit appears functionally sound upon inspection, with minimal cosmetic wear. Though testing was limited, it powers on successfully and conducts basic diagnostic checks without major issues. It utilizes Agilent 2100 expert software for secure data output without computer or software CDs included.
Key Features
- Microfluidics-based platform
- Electrophoresis and flow cytometry
- Process up to 12 samples per run
- 30-45 minute analysis time
- Accurate DNA and protein quantification
- Real-time data display
Specifications
- Analysis Run Time: 30 to 45 minutes
- Sample Capacity: Up to 12 samples/chip
- Sample Volume: 1 µL
- Sizing Range: 50 to 7000 bp
- Operating Temperature: 5 to 40°C (41 to 104°F)
- Voltage: 120V/220V
- Frequency: 50Hz/60Hz
Weight
Imperial: 24.0 Pounds
Metric: 10.89 Kilograms
Shipping Dimensions
Imperial: 19.2 lb x 7.2 lb x 13.2 lb
Metric: 48.77 cm x 18.29 cm x 33.53 cm
Harmonized Code
902780
Harmonized Code Details
902780: 'Instruments and apparatus for physical or chemical analysis'. This code is chosen as the Agilent 2100 Bioanalyzer is used for chemical analysis in laboratory settings.
Comments 0
There are currently no public comments.